Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 2/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067971 | 0.87 | EPAS1 (0.52) | EPAS1NR3C1PKMTRPA1ALDH1A1 | |
| SCHEMBL30444289 | 0.87 | EPAS1 (0.52) | EPAS1NR3C1PKMTRPA1ALDH1A1 | |
| SCHEMBL20384450 | 0.86 | EPAS1 (0.51) | EPAS1NR3C1PKMTRPA1ALDH1A1 | |
| SCHEMBL31440656 | 0.83 | EPAS1 (0.46) | EPAS1NR3C1PKMTRPA1ALDH1A1 | |
| SCHEMBL20155320 | 0.83 | BRD4 (0.43) | EPAS1TRPA1CYP4F2CYP4A11HSPB1 | |
| SCHEMBL21190859 | 0.82 | TTR (0.50) | EPAS1NR3C1PKMMEN1KMT2A | |
| SCHEMBL15068139 | 0.82 | EPAS1 (0.48) | EPAS1NR3C1PKMTRPA1ALDH1A1 | |
| SCHEMBL28927298 | 0.81 | EPAS1 (0.47) | EPAS1NR3C1PKMTRPA1ALDH1A1 | |
| SCHEMBL15067636 | 0.80 | EPAS1 (0.55) | EPAS1NR3C1BRD4 | |
| SCHEMBL15067800 | 0.80 | TRPA1 (0.43) | EPAS1PKMTRPA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116135858-B | Furanopyridone compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2025-04-01 | — | — | CN | disclosed |
| CN-119684283-A | Pyrrolo [2,3-c ] pyridines and use thereof | 山东新时代药业有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024193527-A1 | PYRROLO[2,3-C]PYRIDINE COMPOUND AS BROMODOMAIN INHIBITOR | 山东新时代药业有限公司 | 2024-09-26 | — | — | WO | disclosed |
| CN-118666835-A | Pyrrolo [2,3-c ] pyridines as bromodomain inhibitors | 山东新时代药业有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023088493-A1 | FURO-PYRIDONE COMPOUND AND USE THEREOF | 中国科学院广州生物医药与健康研究院 | 2023-05-25 | — | — | WO | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-116135858-A | Furanopyridone compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-05-19 | — | — | CN | disclosed |
| CN-110167939-B | Pyrrolo [2,3-c ] pyridine derivatives, preparation method and medical application thereof | 江苏豪森药业集团有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-110198941-B | Pyrrolopyridine N-oxide derivative and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| EP-2858990-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | AbbVie Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014165143-A1 | DIHYDRO-PYRROLOPYRIDINONE BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164771-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013188381-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBVIE INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20130331382-A1 | Pyridinone and Pyridazinone Derivatives | ABBVIE INC. | 2013-12-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | EPAS1 2025/4885NR3C1 231/4885PKM 4376/4885 |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | EPAS1 1984/4885NR3C1 377/4885PKM 4223/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | EPAS1 2025/4885NR3C1 231/4885PKM 4376/4885 |
| US-20130331382-A1 | Pyridinone and Pyridazinone Derivatives | CYP4F3, CYP4B1, CYP4F11 | EPAS1 830/4885NR3C1 1480/4885PKM 405/4885 |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | EPAS1 1091/4885NR3C1 929/4885PKM 477/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | EPAS1 2025/4885NR3C1 231/4885PKM 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.